SuperworthArriVent BioPharma price to book ratio AVBP
Market value divided by the book value of the company's net assets, since 2024.
- Today, Oct 23, 2026
- 2.8×
- 2-year median
- 3.2×
- Against its 2-year history
- 26th
- percentile: 0 is its lowest day, 100 its highest
- 2-year range
- 1.9× to 5.0×
- Peer median
- 2.7×
ArriVent BioPharma's price to book ratio is 2.8× as of Oct 23, 2026.
That is below its 2-year median of 3.2×, lower than on 74% of days in the last 2 years.
Over that time it ranged from 1.9× in May 2024 to 5.0× in Jul 2026.
The median for 10 large drugmakers of a similar size is 2.7×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 2.8× | 2.2× | 5.0× |
| 2025 | 3.0× | 2.2× | 4.3× |
| 2024 | 3.3× | 1.9× | 3.9× |
Against its peers
Companies in Drug Manufacturers - General nearest ArriVent BioPharma's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| AVBPArriVent BioPharma | 2.8× |
| AMPHAmphastar Pharmaceuticals | 1.4× |
| OMEROmeros | n/m |
| ABUSArbutus Biopharma | 3.2× |
| COLLCollegium Pharmaceutical | 2.4× |
| PCRXPacira BioSciences | 2.2× |
| ANABAnaptysbio | 138× |
| PAHCPhibro Animal Health | 4.1× |
| ANIPANI Pharmaceuticals | 2.8× |
| CRMDCorMedix | 1.3× |
| ZVRAZevra Therapeutics | 2.7× |
| Peer median | 2.7× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on ArriVent BioPharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.